Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711074 | 0.88 | KDM4E (0.35) | LMNAALDH1A1KDM4E | |
| SCHEMBL10263645 | 0.79 | LMNA (0.34) | LMNAAPOBEC3AAPOBEC3GALDH1A1MAPT | |
| SCHEMBL13562310 | 0.77 | LMNA (0.33) | LMNAAPOBEC3AAPOBEC3GALDH1A1MAPT | |
| SCHEMBL1160912 | 0.77 | APOBEC3A (0.41) | LGMNLMNAAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL9749472 | 0.72 | MAPT (0.35) | LMNAAPOBEC3AAPOBEC3GALDH1A1MAPT | |
| SCHEMBL27793746 | 0.71 | LMNA (0.43) | LGMNLMNAAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL14630673 | 0.70 | APOBEC3A (0.36) | LMNAAPOBEC3AAPOBEC3GALDH1A1MAPT | |
| SCHEMBL612703 | 0.67 | LGMN (0.37) | LGMNLMNAAPOBEC3GALDH1A1MAPT | |
| SCHEMBL24716832 | 0.66 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14779490 | 0.66 | POLB (0.31) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013148851-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2460794-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | HRH4, HRH3, HRH2 | LGMN 4875/4885LMNA 4319/4885APOBEC3A 4114/4885 |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | LGMN 251/4885LMNA 616/4885APOBEC3A 3946/4885 |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | LGMN 251/4885LMNA 616/4885APOBEC3A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.